

James E Tisdale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3409548/publications.pdf>

Version: 2024-02-01

97
papers

3,094
citations

201674

27
h-index

161849

54
g-index

108
all docs

108
docs citations

108
times ranked

3473
citing authors

#	ARTICLE	IF	CITATIONS
1	MsFLASH analysis of diurnal salivary cortisol and palpitations in peri- and postmenopausal women. <i>Menopause</i> , 2022, 29, 144-150.	2.0	3
2	Traditional risk factors for QT interval prolongation and torsades de pointes. , 2022, , 79-111.		0
3	Predictive analytics for reducing the risk of QT interval prolongation and torsades de pointes. , 2022, , 157-181.		0
4	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	4.8	6
5	Drug Interactions Affecting Oral Anticoagulant Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, .	4.8	13
6	Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	2
7	Testosterone does not shorten action potential duration in Langendorff-perfused rabbit ventricles. <i>Heart Rhythm</i> , 2022, 19, 1864-1871.	0.7	1
8	Correlates of palpitations during menopause: A scoping review. <i>Women's Health</i> , 2022, 18, 174550572211122.	1.5	1
9	Transdermal Testosterone Attenuates Drug-Induced Lengthening of Both Early and Late Ventricular Repolarization in Older Men. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1499-1504.	4.7	1
10	A Menopause Strategies-“Finding Lasting Answers for Symptoms and Health (MsFLASH) Investigation of Self-Reported Menopausal Palpitation Distress. <i>Journal of Women's Health</i> , 2021, 30, 533-538.	3.3	11
11	Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. <i>Pharmacotherapy</i> , 2021, 41, 238-246.	2.6	10
12	Accuracy of a single-lead mobile smartphone electrocardiogram for QT interval measurement in patients undergoing maintenance methadone therapy. <i>Pharmacotherapy</i> , 2021, 41, 494-500.	2.6	2
13	Review of menopausal palpitations measures. <i>Women's Midlife Health</i> , 2021, 7, 5.	1.5	8
14	Effect of menopausal symptom treatment options on palpitations: a systematic review. <i>Climacteric</i> , 2021, , 1-13.	2.4	2
15	A Systematic Review of Palpitations Prevalence by Menopausal Status. <i>Current Obstetrics and Gynecology Reports</i> , 2021, 10, 7-13.	0.8	12
16	Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 5-26.	1.3	36
17	Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e214-e233.	1.6	136
18	Enhanced Response to Drug-Induced QT Interval Lengthening in Patients with Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 781-785.	1.7	2

#	ARTICLE	IF	CITATIONS
19	Chloroquine and Hydroxychloroquine in the Era of SARS-CoV2: Caution on Their Cardiac Toxicity. <i>Pharmacotherapy</i> , 2020, 40, 387-388.	2.6	24
20	Pharmacists and Cardiologists in the ACC. <i>Journal of the American College of Cardiology</i> , 2019, 74, 470-472.	2.8	1
21	Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men. <i>Circulation</i> , 2019, 140, 1127-1129.	1.6	14
22	Proarrhythmic food for thought. <i>Heart Rhythm</i> , 2019, 16, 1149-1150.	0.7	4
23	Progesterone pretreatment reduces the incidence of drug-induced torsades de pointes in atrioventricular node-ablated isolated perfused rabbit hearts. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 941-949.	1.7	5
24	Amiodarone for prevention of atrial fibrillation following esophagectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 301-310.e1.	0.8	9
25	Navigating the Minefield of QTc Interval-Prolonging Therapy in Nursing Facility Residents. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1508-1515.	2.6	3
26	Progesterone Metabolites Inhibit the Human Ether A-Go-Related Gene and Predict QT Interval Length. <i>Journal of Clinical Pharmacology</i> , 2019, 60, 648.	2.0	2
27	Editorial commentary: Amiodarone-induced thyroid diseases: Additional unintended consequences. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 296-297.	4.9	1
28	Ondansetron blocks wild-type and p.F503L variant small-conductance Ca ²⁺ -activated K ⁺ channels. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H375-H388.	3.2	18
29	Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation: A Systematic Review. <i>Pharmacotherapy</i> , 2018, 38, 813-821.	2.6	34
30	Research Conducted by Hospital Pharmacists: Integral Component of Daily Practice or Unrealistic Expectation?. <i>Canadian Journal of Hospital Pharmacy</i> , 2018, 71, 95-96.	0.1	1
31	Prevalence and significance of acquired QT interval prolongation in hospitalized patients. <i>Heart Rhythm</i> , 2017, 14, 979-980.	0.7	4
32	Contribution of medications and risk factors to QTc interval lengthening in the atherosclerosis risk in communities (ARIC) study. <i>Journal of Evaluation in Clinical Practice</i> , 2017, 23, 1274-1280.	1.8	6
33	Editorial Commentary: Optimization of dose selection for nonvitamin K antagonist oral anticoagulants. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 573-574.	4.9	0
34	Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 183-4.	0.1	2
35	Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing. <i>Applied Clinical Informatics</i> , 2016, 07, 1088-1106.	1.7	16
36	Efavirenz Inhibits the Human Ether A-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6 Allele Carriers. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 1206-1213.	1.7	35

#	ARTICLE	IF	CITATIONS
37	Drug-induced QT interval prolongation and torsades de pointes. Canadian Pharmacists Journal, 2016, 149, 139-152.	0.8	151
38	Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening. JACC: Clinical Electrophysiology, 2016, 2, 765-774.	3.2	23
39	Influence of Zoledronic Acid on Atrial Electrophysiological Parameters and Electrocardiographic Measurements. Journal of Cardiovascular Electrophysiology, 2015, 26, 671-677.	1.7	7
40	Abstract 19035: Cardiovascular QTc Interval-Prolonging Medications and the Risk of Death, Stroke and Incident Atrial Fibrillation in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2015, 132, .	1.6	0
41	Can I Get a Guideline to Help Me Interpret Treatment Guidelines?. Canadian Journal of Hospital Pharmacy, 2014, 67, 181-2.	0.1	0
42	Effectiveness of a Clinical Decision Support System for Reducing the Risk of QT Interval Prolongation in Hospitalized Patients. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 381-390.	2.2	64
43	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 772-791.	0.8	69
44	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, e153-e193.	0.8	236
45	What Causes Some Patients with Drug-Induced QT Interval Prolongation to Develop Torsades de Pointes but Not Others? The Elusive Missing Link. Drugs and Aging, 2014, 31, 577-579.	2.7	4
46	Abstract 18740: Influence of Oral Progesterone Administration on QT Interval Response to Ikr Inhibition. Circulation, 2014, 130, .	1.6	0
47	Abstract 13786: Contribution of Medications and Risk Factors to QT Interval Lengthening in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2014, 130, .	1.6	0
48	Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel Approach to Guide Renal Dose Adjustments. American Journal of Kidney Diseases, 2013, 61, 1046-1048.	1.9	8
49	QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Current Medical Research and Opinion, 2013, 29, 1719-1726.	1.9	175
50	Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 479-487.	2.2	275
51	High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4495-4499.	3.2	17
52	Enhanced Sensitivity to Drug-Induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction. Journal of Clinical Pharmacology, 2012, 52, 1296-1305.	2.0	16
53	Prevalence of QT Interval Prolongation in Patients Admitted to Cardiac Care Units and Frequency of Subsequent Administration of QT Interval-Prolonging Drugs. Drug Safety, 2012, 35, 459-470.	3.2	74
54	Drug-Induced Atrial Fibrillation. Drugs, 2012, 72, 1617-1630.	10.9	57

#	ARTICLE	IF	CITATIONS
55	Experiential Training for Pharmacy Students: Time for a New Approach. Canadian Journal of Hospital Pharmacy, 2012, 65, 285-93.	0.1	40
56	Hospital Pharmacy in Canada: Ahead of the Curve. Canadian Journal of Hospital Pharmacy, 2012, 65, 345-50.	0.1	0
57	Toward a Unified Model for Contemporary Institutional Pharmacy Practice. Canadian Journal of Hospital Pharmacy, 2011, 64, 97-103.	0.1	0
58	The Influence of Progesterone Alone and in Combination With Estradiol on Ventricular Action Potential Duration and Triangulation in Response to Potassium Channel Inhibition. Journal of Cardiovascular Electrophysiology, 2011, 22, 325-331.	1.7	11
59	The Society of Thoracic Surgeons Practice Guideline on the Prophylaxis and Management of Atrial Fibrillation Associated With General Thoracic Surgery: Executive Summary. Annals of Thoracic Surgery, 2011, 92, 1144-1152.	1.3	109
60	A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 45-51.	0.8	97
61	Prophylaxis of Atrial Fibrillation After Noncardiac Thoracic Surgery. Seminars in Thoracic and Cardiovascular Surgery, 2010, 22, 310-320.	0.6	26
62	Integrity in Authorship and Publication. Canadian Journal of Hospital Pharmacy, 2009, 62, 441-7.	0.1	2
63	A Randomized Trial Evaluating Amiodarone for Prevention of Atrial Fibrillation After Pulmonary Resection. Annals of Thoracic Surgery, 2009, 88, 886-895.	1.3	93
64	Paroxysmal I^2 -adrenergic Receptor-mediated Alterations in Ventricular Repolarization at Rapid Heart Rates During Inhibition of Delayed Rectifier Currents. Journal of Cardiovascular Pharmacology, 2009, 54, 253-262.	1.9	1
65	Pharmacokinetics of Ibutilide in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction. Pharmacotherapy, 2008, 28, 1461-1470.	2.6	13
66	Effect of Drugs on Defibrillation Capacity. Drugs, 2008, 68, 607-630.	10.9	40
67	Prospective evaluation of serum amiodarone concentrations when administered via a nasogastric tube into the stomach conduit after transthoracic esophagectomy. Clinical Therapeutics, 2007, 29, 2226-2234.	2.5	7
68	Accuracy of Uncorrected versus Corrected QT Interval for Prediction of Torsade de Pointes Associated with Intravenous Haloperidol. Pharmacotherapy, 2007, 27, 175-182.	2.6	21
69	Hemodynamic and Neurohormonal Predictors and Consequences of the Development of Atrial Fibrillation in Dogs With Chronic Heart Failure. Journal of Cardiac Failure, 2006, 12, 747-751.	1.7	20
70	Role of the pharmacist in managing hypertension in patients with diabetes. American Journal of Health-System Pharmacy, 2006, 63, 1129-1129.	1.0	1
71	Risk factors for hypertensive crisis: importance of out-patient blood pressure control. Family Practice, 2004, 21, 420-424.	1.9	52
72	Influence of IV Haloperidol on Ventricular Repolarization and Monophasic Action Potential Duration in Anesthetized Dogs. Chest, 2004, 125, 1821-1829.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 242-247.	4.7	58
74	Erratum to "The Effect of Intravenous Haloperidol on QT Interval Dispersion in Critically Ill Patients: Comparison with QT Interval Prolongation for Assessment of Risk of Torsades de Pointes" [J Clin Pharmacol 2001;41:1310-1318]. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 577-579.	2.0	2
75	Bleeding Associated with Eptifibatid Targeting Higher Risk Patients with Acute Coronary Syndromes: Incidence and Multivariate Risk Factors. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1366-1373.	2.0	13
76	The Effect of Intravenous Haloperidol on QT Interval Dispersion in Critically Ill Patients: Comparison with QT Interval Prolongation for Assessment of Risk of Torsades de Pointes. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1310-1318.	2.0	59
77	Pharmacologic conversion of atrial fibrillation: A systematic review of available evidence. <i>Progress in Cardiovascular Diseases</i> , 2001, 44, 121-152.	3.1	64
78	The Use of Calcium Salts in the Prevention and Management of Verapamil-Induced Hypotension. <i>Annals of Pharmacotherapy</i> , 2000, 34, 622-629.	1.9	11
79	Torsades de Pointes Associated With Intravenous Haloperidol in Critically Ill Patients. <i>American Journal of Cardiology</i> , 1998, 81, 238-240.	1.6	232
80	A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. <i>American Heart Journal</i> , 1998, 135, 739-747.	2.7	91
81	Atrial Fibrillation After Bypass Surgery. <i>Chest</i> , 1998, 113, 1489-1491.	0.8	110
82	Disposition of Procainamide in Patients with Chronic Congestive Heart Failure Receiving Medical Therapy. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 35-41.	2.0	14
83	Antifibrillatory Effect of Esmolol Alone and in Combination with Lidocaine. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 27, 376-382.	1.9	9
84	Comparison of Fluorescence Polarization Immunoassay with Liquid Chromatography for Quantification of Procainamide and N-Acetylprocainamide in Urine. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 693-697.	2.0	1
85	Inhibition of N-Acetylation of Procainamide and Renal Clearance of N-Acetylprocainamide by Para-Aminobenzoic Acid in Humans. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 902-910.	2.0	7
86	Risk Factors for the Development of Specific Noncardiovascular Adverse Effects Associated With Amiodarone. <i>Journal of Clinical Pharmacology</i> , 1995, 35, 351-356.	2.0	41
87	Proarrhythmic Effects of Intravenous Vasopressors. <i>Annals of Pharmacotherapy</i> , 1995, 29, 269-281.	1.9	70
88	Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Progress in Cardiovascular Diseases</i> , 1995, 38, 167-180.	3.1	93
89	Efficacy of Class 1C Antiarrhythmic Agents in Patients With Inducible Ventricular Tachycardia Refractory to Therapy With Class 1A Antiarrhythmic Drugs. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 623-630.	2.0	0
90	Accuracy of unbound-quinidine concentration determination after ultrafiltration. <i>Clinical Pharmacy</i> , 1993, 12, 917-21.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Relationship Between Serum Concentration and Dose of Valproic Acid During Monotherapy in Adult Outpatients. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 416-423.	2.0	13
92	Are antiarrhythmic drugs obsolete?. <i>Clinical Pharmacy</i> , 1992, 11, 714-26.	0.2	0
93	The Effect of Haloperidol on Ventricular Fibrillation Threshold in Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1991, 69, 327-329.	0.0	13
94	Lidocaine prophylaxis in acute myocardial infarction. <i>Henry Ford Hospital Medical Journal</i> , 1991, 39, 217-25.	0.1	7
95	Streptokinase-Induced Anaphylaxis. <i>DICP: the Annals of Pharmacotherapy</i> , 1989, 23, 984-987.	0.2	9
96	Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 1500-1505.	3.2	27
97	Combination antiarrhythmic therapy. <i>Connecticut Medicine</i> , 1989, 53, 101-5.	0.2	0